Get started

Smallcaps

$BYOC On Upward Sideways Trend In Anticipation of Filings$BYOC released an unaudited 8-k yesterday in the first of filings to be dropped similar to $ATPT It is anticipated that the move up past the .03 break will be greater than any and all moves it has made so far once the filings have posted as institutional buying pressure will begin to pour into the stock as many and much greater updates will be released afterwards including acquisitions of 3 Big data companies under the umbrella of the company. A .03 break is possible this week as the chart shows a slight upward sideways movement.
OTC:BYOCLong
by StockGuild
$EHVVF Continues to Move in Anticipation of Canadian MJ+ Updates"We have executed and expanded the commitments we have made to our mental health (Multi Health Systems) and therapeutic partners (MedReleaf TSX: LEAF), entered new partnerships to expand our market verticals to include the pharmaceutical industry (Aequus TSX-V: AQS). Meanwhile, we have been preparing for our next set of trials of our new video games for assessment & remediation of ADD/ADHD developed in collaboration with The Hospital for Sick Children in Toronto." "Pharmaceutical Trials In July 2017, we signed a Letter of Intent with Aequus Pharmaceuticals for Ehave solutions to be used for the assessment, diagnostic, therapeutic and outcome management for use in informal and formal clinical trials. The intent is for the Ehave Platform and patient reported outcomes application to be used by clinicians and patients of Aequus trials, with content to be customized based on the specific needs of the trial protocols for both traditional and Cannabis CBD-based treatments. This is a significant milestone for Ehave – opening up a new market vertical to demonstrate the value of the Ehave informatics platform in clinical trails. We believe that we can bring the cost of trials down substantially and be the first Digital CRO in the market." "We have a management team that has built, grown and operated high value organizations before, including my experience in building a $10M cancer informatics solution for Princess Margaret Cancer Center, being an executive at Mount Sinai Hospital in Toronto that had a $330M operating budget, the $40M exit of Casero to Radial Point where I was a founding employee, and being an early employee of Solect Technology Group which sold to Amdocs for $1.2B. In addition, we have a world class Board of Directors with health technology, pharmaceutical and insurance expertise." 13g Filed A/H's Nov, 9th 2017 Name of Person Filing EISENBERG FAMILY FOUNDATION, INC. Income of over $100 Million. www.taxexemptworld.com ih.advfn.com
OTC:EHVVFLong
by StockGuild
$TVIAQ Could Become Bigger Than $SOUPQ Here's Why1. $118 Million in Assets 2. $60 Million Cash on Hand 3. $25 Million in Sales 4. 225,000,000 A/S 108,000,000 O/S and 80,000,000 Float 5. Monster Partnerships with Bulge and Unilever both $50 Billion Companies 6. Potential partnership with Corbion who paid $20 Million in cash for I/P but made a PowerPoint representing both and kept Terravia's website with direct link to Corbion's. 7. 52 week high of $2.45 and was only delisted from the Nasdaq in August 8. Oh let's not forget: $900,000,000 in NOL's. Happy Trading ;-)
TLong
by StockGuild
1
$GRDO Continues its Uptrend on Higher Accumulation + UpdatesClick this link to read the Massive *Rolling DD Packet* We have put together for this Stock: sunnymoneyfamily.com Here is the news that got released just today: $GRDO News Shareholder letter! International Venture Society Presents the Following Shareholder Updates (OTC PINK: GRDO) International Venture Society (IVS) is pleased to announce that the custodianship proceedings for Guard Dog, Inc. (GRDO), Media G3, Inc. (MDGC) and MC Endeavors, Inc. (MSMY) were successfully adjudicated on its merits and granted in favor of IVS. The company, through its attorneys, will provide to the courts a 90 day status report on progressions made in regard to state charter revival, company reconstruction, merger candidates and regulatory compliance. In order to satisfy obligations to the courts, shareholders and potential merging/acquisition candidates, we will begin taking the necessary steps to seek reinstatement of the Nevada charters in the following weeks. “I am hopeful that the stockholders of the individual companies will view the courts' decision as a vital first step for International Venture Society to construct these long non-operational OTC companies into legitimate businesses once again,”stated International Venture Society CEO Kelani Long. “While our attorneys start working toward charter renewals, I will be evaluating possible business models as well as mergers candidates for the companies.” $GRDO tweet reply from the Company that Bill Shaefer has nothing whatsoever to do with this shell any longer! twitter.com $GRDO tweet on upcoming company updates smile twitter.com FYI in order take-over a stock-shell through_the courts in a Custodianship case as opposed to buying one you have to have a business model and a timeframe for what you are doing. You also have to bring the stock current and follow guidelines set out in the case. A public shell can cost anywhere from $35,000 to $600,000 depending on the shell you are buying. Knowing that surely the courts will make sure a legitimate company will be taking over the symbol. Courts don't just take away and hand out dormant stock shells to someone else with no purpose! This should get very interesting in the coming weeks!!!
GLong
by StockGuild
$VCPS Wine Club and App Patent Approval Could Send This .01+***$VCPS GROUNDBREAKING WINE INDUSTRY APP LAUNCH*** VCPS is an OTC Pink stock that is current and trademarked in the wine industry with a mobile app; patent pending. The wine industry is expected to continue it’s exponential growth in 2017. VinCompass seems to have a leg up on this projection with the amount of effort they have put into their brand. Special Wine club The VinCompass Signature Series Wine Club is a key component of our members' ongoing wine journeys. Featured wines are true to their places of origin, but also demonstrate innovations in winemaking that make them must-haves for those interested in expanding their wine experiences. While not all the featured wines have cellaring potential, they will all bring delight to your table. VinCompass Currently has a Wine Club that will bring in substantial income a rundown of which follows: Wines $50 and under: 3 Per Month $90 Monthly Payment 6 Per Month $180 Monthly Payment 9 Per Month $270 Monthly Payment 12 Per Month $360 Monthly Payment Wines over $50 but under $100: 3 Per Month $180 Monthly Payment 6 Per Month $360 Monthly Payment 9 Per Month $540 Monthly Payment 12 Per Month $720 Monthly Payment Wines over $100: 3 Per Month $270 Monthly Payment 6 Per Month $540 Monthly Payment 9 Per Month $810 Monthly Payment 12 Per Month $1080 Monthly Payment VinCompass is a wine company that is working on a patent pending application similar to Leafly (marijuana) and Zillow (real estate) but for the wine Industry. Their application is downloadable on both the Android and Apple App Stores. Access to their application is currently by invitation only. Per their website you can request an invitation code via staff@vincompass.com (This is thought as a testing phase before the approval of their patent.) Their application is patent pending and has been projected to be granted in 2017. The company has been noticeably busy on OTCMarkets as of June 2017 and the CEO has even purchased 18 million company shares at a higher price than it was worth at the time per Form 5. It is thought that the patent may already be granted and they are getting their filings up to date and buying company stock before announcing anything.
VLong
by StockGuild
$DCTH Mid Term Goals could put this over $1+ In Weeks - Repost -Reposting as it didn't post properly the first time $DCTH Highlights for the first quarter of 2017 and the recent weeks include: First quarter 2017 revenue of $0.74 million, an increase of 100% compared with revenue of $0.37 million in prior year quarter. CHEMOSAT treatment milestone set by SPIRE Southampton Hospital in the U.K. with more than 100 CHEMOSAT treatments performed, including eight treatments on a single patient. Announced a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the design of a pivotal trial of Melphalan/HDS to treat patients with intrahepatic cholangiocarcinoma (ICC). The American Journal of Clinical Oncology published a single-center retrospective review finding that the Company’s investigational percutaneous hepatic perfusion (PHP) with Melphalan/HDS offered promising results with a doubling of overall survival (OS), significantly longer progression-free survival (PFS) and hepatic progression-free survival (hPFS) compared with other targeted therapies. Favorable data from two institutions were presented at the Regional Cancer Therapies Symposium and showed strong tumor response and overall survival with the Company’s investigational PHP therapy in patients with ocular melanoma that metastasized to the liver. “During the first three months of 2017 we continued to advance our clinical development programs in ocular melanoma liver metastases and intrahepatic cholangiocarcinoma, while making steady progress with commercialization of CHEMOSAT in Europe,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath." “As we announced recently, we have concluded a new SPA agreement with the FDA for the initiation of a pivotal trial for the use of Melphalan/HDS in patients with ICC. This new trial will enroll approximately 295 ICC patients at about 40 clinical sites in the U.S. and Europe, with the primary endpoint of overall survival and with secondary and exploratory endpoints that include safety, progression-free survival, objective response rate and quality-of-life measures. The trial is designed to be cost-effective and conducted in a financially prudent manner, with modest investment in this fiscal year. In conjunction with the FOCUS Trial in ocular melanoma liver metastases, our clinical development programs now include two paths toward potential U.S. market approvals. “In Europe, we continue to make steady progress with the commercialization of CHEMOSAT. Our first quarter revenue of more than $0.7 million was double the prior year period’s sales, driven primarily by national reimbursement in Germany under the ZE system. With coverage under the ZE system now in place, we expect product sales growth from this market for the remainder of 2017." "Elsewhere in Europe, we continue to focus on building the clinical and pharmacoeconomic data to support reimbursement applications in other key markets. We expect that positive negotiations for coverage in Germany will support our efforts for payment levels in other markets such as the U.K. and the Netherlands. Securing reimbursement coverage in additional European markets remains critical to future revenue growth for CHEMOSAT,” concluded Dr. Simpson. As of March 31, 2017, Delcath had cash and cash equivalents of $6.4 million, compared with $4.4 million as of December 31, 2016. During the first quarter of 2017, the Company used $3.8 million of cash to fund operating activities. Delcath believes it has sufficient capital and access to committed capital to fund its operating activities through the end of 2017. Also check out this article, pretty good read: insiderfinancial.com
NASDAQ:DCTHLong
by StockGuild
MRPHF MJ-PlayCompany Name: Marapharm Ventures Inc. Stock Symbol: MRPHF Company Website: www.marapharm.com Trading at approx $0.57 Per Share (10/26/2016) MRPHF released news today: The company gave a corporate update on several key developments in its wholly owned US subsidiary in Las Vegas, Nevada. Read the press release using the link below : finance.yahoo.com MRPHF is a fresh marijuana stock. With 5 states voting on recreational marijuana legalization, the marijuana sector is getting some serious attention like in 2014. This tightly held float can easily run up so dont sleep on this one. Continue reading at: www.stockpicksnyc.com
MLong
by StockPicksNYC
Can TGMA3 recover it's historic price?In the last 12 months, the market value of Tegma (TGMA3) has decreased about 80% (06/01/2016 - $14.30 H; 01/27/2016 - $2.86 L). This company, which corebusiness is the transportation of new vehicles from factories to distributors, saw its revenues dwindle in face of the reduction of Brazilian consumer and employer confidence levels, the gloomy prospects for the country's interest rates, the growth of debt and default of families and the beginning of an unemployment crisis that still committs over 10% of the economically active population of the country: Not a good scenario to buy a car, I'd say. Several months latter, thinks start to change with the prospect of success of impeachment of president Dilma Rousseff, and another bunch of events may help to a faster recover of economy in the country, which I'll resume in one consequence: The return of huge ammounts of foreign capital. TGMA3 has done good job in surviving the worst point of the crisis. The question is: when will the Brazilian market recover the hability to stand an grown?
BMFBOVESPA:TGMA3Long
by Inativo